Statement 28 May 2024

WHA77 individual statement on the Working Group on Amendments to the International Health Regulations (2005)

By IFPMA
Downloads
Statement
Share
Topics

On 28 May 2024, IFPMA submitted a statement at the World Health Assembly on Provisional Agenda Item 13.3, Working Group on Amendments to the International Health Regulations (2005).

IFPMA acknowledges and appreciates the substantial efforts made by Member States in advancing the text of the Working Group on Amendments to the International Health Regulations (WGIHR). We recognize the dedication and collaboration that have brought us to this stage, reflecting a shared commitment.

The pharmaceutical industry is committed to the principle of equity in global health. However, while progress has been made, the current draft still has open issues that may present challenges and have a counterproductive impact

The lack of clarity on many key definitions and the ongoing discussions at the Intergovernmental Negotiating Body (INB), which are cross-referenced in the document, complicate our ability to fully assess and provide comprehensive feedback on the proposed amendments. In addition, we urge Member States to ensure that technology transfer remains voluntary and on mutually agreed terms.

We remain committed to working with Member States and stakeholders to achieve a robust and successful outcome.

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.

Learn more

Media Contact

Elliot Dunster
Top